Two of Huadong Medicine's (SHE:000963) drugs were included in China's National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List, according to a Shenzhen bourse filing on Monday.
The drugs are senaparib capsules and lina-raserate dimethyl ester capsules.
The new list will be effective on Jan. 1, 2026, the Chinese drugmaker said.
Meanwhile, the company's zevokio lensa injection was included in the commercial health insurance innovative drug list, while the ustekinumab injection was moved to routine catalog management, with changes to its reimbursement scope.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments